<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38932299</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Milk of Cows Immunized with Trivalent Inactivated Vaccines Provides Broad-Spectrum Passive Protection against Hand, Foot, and Mouth Disease in Neonatal Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">570</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12060570</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) is a contagious viral infection predominantly affecting infants and young children, caused by multiple enteroviruses, including Enterovirus 71 (EV71), Coxsackievirus A16 (CA16), Coxsackievirus A10 (CA10), and Coxsackievirus A6 (CA6). The high pathogenicity of HFMD has garnered significant attention. Currently, there is no specific treatment or broad-spectrum preventive measure available for HFMD, and existing monovalent vaccines have limited impact on the overall incidence or prevalence of the disease. Consequently, with the emergence of new viral strains driven by vaccine pressure, there is an urgent need to develop strategies for the rapid response and control of new outbreaks. In this study, we demonstrated the broad protective effect of maternal antibodies against three types of HFMD by immunizing mother mice with a trivalent inactivated vaccine targeting EV71, CA16, and CA10, using a neonatal mouse challenge model. Based on the feasibility of maternal antibodies as a form of passive immunization to prevent HFMD, we prepared a multivalent antiviral milk by immunizing dairy cows with the trivalent inactivated vaccine to target multiple HFMD viruses. In the neonatal mouse challenge model, this immunized milk exhibited extensive passive protection against oral infections caused by the three HFMD viruses. Compared to vaccines, this strategy may offer a rapid and broadly applicable approach to providing passive immunity for the prevention of HFMD, particularly in response to the swift emergence and spread of new variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6660-0242</Identifier><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Wanjun</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8395-324X</Identifier><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hekai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gengxin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gaoying</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Wuhan Servicebio Technology Co., Ltd., Wuhan 430079, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0214-2224</Identifier><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiangning</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1264-6664</Identifier><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-I2M-1-020</GrantID><Agency>CAMS Innovation Fund for Medical Sciences (CIFMS)</Agency><Country /></Grant><Grant><GrantID>92169210</GrantID><Agency>National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>2022YFC2303404</GrantID><Agency>National Key Research and Development Project of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">maternal antibody</Keyword><Keyword MajorTopicYN="N">multivalent antiviral milk</Keyword><Keyword MajorTopicYN="N">neonatal mouse challenge model</Keyword><Keyword MajorTopicYN="N">passive immune protection</Keyword></KeywordList><CoiStatement>G.Z. (Gaoying Zhang) was employed by Wuhan Servicebio Technology Co., Ltd. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be interpreted as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932299</ArticleId><ArticleId IdType="pmc">PMC11209096</ArticleId><ArticleId IdType="doi">10.3390/vaccines12060570</ArticleId><ArticleId IdType="pii">vaccines12060570</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fischer T.K., Nielsen A.Y., Sydenham T.V., Andersen P.H., Andersen B., Midgley S.E. Emergence of enterovirus 71 C4a in Denmark, 2009 to 2013. Euro Surveill. Bull. Eur. Sur Les Mal. Transm. = Eur. Commun. Dis. Bull. 2014;19:20911. doi: 10.2807/1560-7917.es2014.19.38.20911.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es2014.19.38.20911</ArticleId><ArticleId IdType="pubmed">25306878</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones E., Pillay T.D., Liu F., Luo L., Bazo-Alvarez J.C., Yuan C., Zhao S., Chen Q., Li Y., Liao Q., et al. Outcomes following severe hand foot and mouth disease: A systematic review and meta-analysis. Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc. 2018;22:763–773. doi: 10.1016/j.ejpn.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpn.2018.04.007</ArticleId><ArticleId IdType="pmc">PMC6148319</ArticleId><ArticleId IdType="pubmed">29778429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T., Han T., Tan X., Zhu S., Yan D., Yang Q., Song Y., Cui A., Zhang Y., Mao N., et al. Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from 2008 to 2017. Biosaf. Health. 2019;1:32–40. doi: 10.1016/j.bsheal.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2019.02.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Huang L.M., Gau S.S., Wu Y.Y., Hsia S.H., Fan T.Y., Lin K.L., Huang Y.C., Lu C.Y., Lin T.Y. Neurodevelopment and cognition in children after enterovirus 71 infection. N. Engl. J. Med. 2007;356:1226–1234. doi: 10.1056/NEJMoa065954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa065954</ArticleId><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008–2012: An epidemiological study. Lancet Infect. Dis. 2014;14:308–318. doi: 10.1016/s1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M.C., Wang S.M., Hsu Y.W., Lin H.C., Chi C.Y., Liu C.C. Long-term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics. 2006;118:e1785–e1788. doi: 10.1542/peds.2006-1547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-1547</ArticleId><ArticleId IdType="pubmed">17116698</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Zhang C., Wang X., Ren X., Peng H., Tang X., Zhang L., Chen Z., Ye Y., Zheng M., et al. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017–2022: A descriptive study. Emerg. Microbes Infect. 2022;11:2510–2519. doi: 10.1080/22221751.2022.2125346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2125346</ArticleId><ArticleId IdType="pmc">PMC9621254</ArticleId><ArticleId IdType="pubmed">36103331</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui J., Luo K., Chen Q., Zhang D., Zhao Q., Zhang Y., Zhai X., Zhao Z., Zhang S., Liao Y., et al. Early warning of hand, foot, and mouth disease transmission: A modeling study in mainland, China. PLoS Negl. Trop. Dis. 2021;15:e0009233. doi: 10.1371/journal.pntd.0009233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0009233</ArticleId><ArticleId IdType="pmc">PMC8021164</ArticleId><ArticleId IdType="pubmed">33760810</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., Mao N., Xu S., Zhu S., Cui A., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 2010;7:94. doi: 10.1186/1743-422x-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422x-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S., Arunkumar G., Alidjinou E.K., Hober D. Hand, foot and mouth disease (HFMD): Emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 2016;205:397–407. doi: 10.1007/s00430-016-0465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prinzio A., Bastard D.P., Torre A.C., Mazzuoccolo L.D. Hand, foot, and mouth disease in adults caused by Coxsackievirus B1–B6. An. Bras. Dermatol. 2022;97:321–325. doi: 10.1016/j.abd.2021.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abd.2021.03.012</ArticleId><ArticleId IdType="pmc">PMC9133263</ArticleId><ArticleId IdType="pubmed">35272920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q.Y., Wang Y., Bian L., Xu M., Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) Expert Rev. Vaccines. 2016;15:599–606. doi: 10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032. doi: 10.1016/s0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Liu Y., Li S., Zhao H., Lin Q., Yu H., Huang X., Zheng Q., Cheng T., Xia N. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine. 2016;34:5938–5945. doi: 10.1016/j.vaccine.2016.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.018</ArticleId><ArticleId IdType="pubmed">27771182</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Liao Q., Ooi M.H., Cowling B.J., Chang Z., Wu P., Liu F., Li Y., Luo L., Yu S., et al. Epidemiology of Recurrent Hand, Foot and Mouth Disease, China, 2008–2015. Emerg. Infect. Dis. 2018;24:432–442. doi: 10.3201/eid2403.171303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2403.171303</ArticleId><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Li H., Yue L., Song X., Xie T., Ma S., Meng H., Zhang Y., He X., Long R., et al. A comparative study of multiple clinical enterovirus 71 isolates and evaluation of cross protection of inactivated vaccine strain FY-23 K-B in vitro. Virol. J. 2017;14:206. doi: 10.1186/s12985-017-0872-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0872-8</ArticleId><ArticleId IdType="pmc">PMC5659012</ArticleId><ArticleId IdType="pubmed">29073897</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhou Y., Cheng Y., Wu P., Zhou C., Cui P., Song C., Liang L., Wang F., Qiu Q., et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–2018: A test-negative case-control study. Lancet Child Adolesc. Health. 2019;3:697–704. doi: 10.1016/s2352-4642(19)30185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang L., Zhang C., He W., Tan Y., Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39:3319–3323. doi: 10.1016/j.vaccine.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.009</ArticleId><ArticleId IdType="pubmed">33994239</ArticleId></ArticleIdList></Reference><Reference><Citation>Head J.R., Collender P.A., Lewnard J.A., Skaff N.K., Li L., Cheng Q., Baker J.M., Li C., Chen D., Ohringer A., et al. Early Evidence of Inactivated Enterovirus 71 Vaccine Impact Against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011–2018: A Longitudinal Surveillance Study. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020;71:3088–3095. doi: 10.1093/cid/ciz1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1188</ArticleId><ArticleId IdType="pmc">PMC7819528</ArticleId><ArticleId IdType="pubmed">31879754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2015;60:797–803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z., Huang Y., Bloom M.S., Zhang Z., Yang Z., Lu J., Xu J., Hao Y. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: A time-series analysis. Hum. Vaccines Immunother. 2021;17:217–223. doi: 10.1080/21645515.2020.1763076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1763076</ArticleId><ArticleId IdType="pmc">PMC7872061</ArticleId><ArticleId IdType="pubmed">32530733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M., Takeichi T., Muramatsu H., Kojima D., Osada Y., Kono M., Kojima S., Akiyama M. Recurrent Cellulitis Caused by Helicobacter cinaedi in a Patient with X-linked Agammaglobulinaemia. Acta Derm.-Venereol. 2017;97:277–278. doi: 10.2340/00015555-2501.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-2501</ArticleId><ArticleId IdType="pubmed">27377098</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendran N., Nicolosi T., Kaur R., Morris M., Pichichero M. Prospective study of the innate cellular immune response in low vaccine responder children. Innate Immun. 2017;23:89–96. doi: 10.1177/1753425916678471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425916678471</ArticleId><ArticleId IdType="pubmed">27864558</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch R.M., Kox M., de Jonge M.I., van der Hoeven J.G., Ferwerda G., Pickkers P. Patterns in Bacterial- and Viral-Induced Immunosuppression and Secondary Infections in the ICU. Shock. 2017;47:5–12. doi: 10.1097/shk.0000000000000731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/shk.0000000000000731</ArticleId><ArticleId IdType="pubmed">27517143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichichero M.E. Challenges in vaccination of neonates, infants and young children. Vaccine. 2014;32:3886–3894. doi: 10.1016/j.vaccine.2014.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.05.008</ArticleId><ArticleId IdType="pmc">PMC4135535</ArticleId><ArticleId IdType="pubmed">24837502</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Tong X., Huang Z. Towards broadly protective polyvalent vaccines against hand, foot and mouth disease. Microbes Infect. 2015;17:155–162. doi: 10.1016/j.micinf.2014.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2014.11.004</ArticleId><ArticleId IdType="pubmed">25449959</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M.H. EV71 vaccines: A first step towards multivalent hand, foot and mouth disease vaccines. Expert Rev. Vaccines. 2015;14:337–340. doi: 10.1586/14760584.2015.993385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.993385</ArticleId><ArticleId IdType="pubmed">25536888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Gao H.H., Zhang Q., Liu Y.J., Tao R., Cheng Y.P., Shu Q., Shang S.Q. Large outbreak of herpangina in children caused by enterovirus in summer of 2015 in Hangzhou, China. Sci. Rep. 2016;6:35388. doi: 10.1038/srep35388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35388</ArticleId><ArticleId IdType="pmc">PMC5067559</ArticleId><ArticleId IdType="pubmed">27752104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., He S., Yan Q., Xu X., Wu W., Ge S., Zhang S., Chen M., Xia N. Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2017;93:20–24. doi: 10.1016/j.jcv.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.011</ArticleId><ArticleId IdType="pubmed">28577423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Zhang T., Hu Y., Wang X., Du J., Li Y., Sun S., Sun X., Li Z., Jin Q. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol. J. 2011;8:508. doi: 10.1186/1743-422x-8-508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422x-8-508</ArticleId><ArticleId IdType="pmc">PMC3227625</ArticleId><ArticleId IdType="pubmed">22054534</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2018;37:391–398. doi: 10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.H., Choi S.S., Oh S.A., Kim C.K., Cho S.J., Lee J.H., Ryu S.H., Pak S.H., Jung S.K., Lee J.I., et al. Detection and characterization of enterovirus associated with herpangina and hand, foot, and mouth disease in Seoul, Korea. Clin. Lab. 2011;57:959–967.</Citation><ArticleIdList><ArticleId IdType="pubmed">22239028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Liu F., Liao Q., Wu P., Chang Z., Huang J., Long L., Luo L., Li Y., Leung G.M., et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. Bull. Eur. Sur Les Mal. Transm. = Eur. Commun. Dis. Bull. 2017;22:16-00824. doi: 10.2807/1560-7917.es.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Wu P., Wu J.T., Lau E.H., Leung G.M., Yu H., Cowling B.J. Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis. Pediatr. Infect. Dis. J. 2015;34:1399–1406. doi: 10.1097/inf.0000000000000900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/inf.0000000000000900</ArticleId><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S.T., Chiang P.S., Chao A.S., Liou G.Y., Lin R., Lin T.Y., Lee M.S. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg. Infect. Dis. 2009;15:581–584. doi: 10.3201/eid1504.081550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1504.081550</ArticleId><ArticleId IdType="pmc">PMC2671432</ArticleId><ArticleId IdType="pubmed">19331737</ArticleId></ArticleIdList></Reference><Reference><Citation>Atyeo C., Alter G. The multifaceted roles of breast milk antibodies. Cell. 2021;184:1486–1499. doi: 10.1016/j.cell.2021.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.031</ArticleId><ArticleId IdType="pubmed">33740451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Wang Q., Carr M.J., Li J., Liu T., Li D., Shi W. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36:7095–7104. doi: 10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine E.A., Fuchs J., Das S.C., Partidos C.D., Osorio J.E. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice. Viruses. 2015;7:5919–5932. doi: 10.3390/v7112916.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck Z.Y., Enterlein S.G., Howell K.A., Vu H., Shulenin S., Warfield K.L., Froude J.W., Araghi N., Douglas R., Biggins J., et al. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. J. Virol. 2016;90:279–291. doi: 10.1128/jvi.02172-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02172-15</ArticleId><ArticleId IdType="pmc">PMC4702572</ArticleId><ArticleId IdType="pubmed">26468532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustinx W.N., Kraaijeveld K., Hoepelman A.I., Verhoef J. Cross-protection by anti-core glycolipid antibodies: Evidence from animal experiments. J. Antimicrob. Chemother. 1997;40:475–483. doi: 10.1093/jac/40.4.475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/40.4.475</ArticleId><ArticleId IdType="pubmed">9372415</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhara S. Can Drinking Microfiltered Raw Immune Milk From Cows Immunized Against SARS-CoV-2 Provide Short-Term Protection Against COVID-19? Front. Immunol. 2020;11:1888. doi: 10.3389/fimmu.2020.01888.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01888</ArticleId><ArticleId IdType="pmc">PMC7399080</ArticleId><ArticleId IdType="pubmed">32849647</ArticleId></ArticleIdList></Reference><Reference><Citation>Garib V., Katsamaki S., Turdikulova S., Levitskaya Y., Zahidova N., Bus G., Karamova K., Rakhmedova M., Magbulova N., Bruhov A., et al. Milk of Cow and Goat, Immunized by Recombinant Protein Vaccine ZF-UZ-VAC2001(Zifivax), Contains Neutralizing Antibodies Against SARS-CoV-2 and Remains Active After Standard Milk Pasteurization. Front. Nutr. 2022;9:901871. doi: 10.3389/fnut.2022.901871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.901871</ArticleId><ArticleId IdType="pmc">PMC9249723</ArticleId><ArticleId IdType="pubmed">35789966</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerswald H., Yann S., Dul S., In S., Dussart P., Martin N.J., Karlsson E.A., Garcia-Rivera J.A. Assessment of inactivation procedures for SARS-CoV-2. J. Gen. Virol. 2021;102:001539. doi: 10.1099/jgv.0.001539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001539</ArticleId><ArticleId IdType="pmc">PMC8148305</ArticleId><ArticleId IdType="pubmed">33416462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E., Cheng C., Zhang Y., Wang J., Che Y., Pu J., Dong C., Liu L., He Z., Lu S., et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum. Vaccines Immunother. 2014;10:1266–1273. doi: 10.4161/hv.28083.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28083</ArticleId><ArticleId IdType="pmc">PMC4896597</ArticleId><ArticleId IdType="pubmed">24583556</ArticleId></ArticleIdList></Reference><Reference><Citation>Laboratory Animal — Requirements of Environment and Housing Facilities. Standards Press of China; Beijing, China: 2011.</Citation></Reference><Reference><Citation>Li S., Zhao H., Yang L., Hou W., Xu L., Wu Y., Wang W., Chen C., Wan J., Ye X., et al. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antivir. Res. 2017;144:247–255. doi: 10.1016/j.antiviral.2017.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.06.008</ArticleId><ArticleId IdType="pubmed">28625478</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., Wang C., Mao P., Liang Z., Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J. Virol. 2012;86:11967–11976. doi: 10.1128/jvi.00902-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.L., Lee Y.P., Wang Y.F., Lei H.Y., Liu C.C., Wang S.M., Su I.J., Wang J.R., Yeh T.M., Chen S.H., et al. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 2005;86:3263–3269. doi: 10.1099/vir.0.81195-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81195-0</ArticleId><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Van H.M.T., Anh N.T., Hong N.T.T., Nhu L.N.T., Nguyet L.A., Thanh T.T., Ny N.T.H., Hang V.T.T., Khanh T.H., Viet H.L., et al. Enterovirus A71 Phenotypes Causing Hand, Foot and Mouth Disease, Vietnam. Emerg. Infect. Dis. 2019;25:788–791. doi: 10.3201/eid2504.181367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2504.181367</ArticleId><ArticleId IdType="pmc">PMC6433038</ArticleId><ArticleId IdType="pubmed">30882309</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W.P., Chen G.Q., Xie G.C., Du L.Y., Tang Q. Mosaic genome of Human Coxsackievirus A4 associated with herpangina and HFMD in Yancheng, China, 2016 and 2018. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2020;96:538–540. doi: 10.1016/j.ijid.2020.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.057</ArticleId><ArticleId IdType="pubmed">32439540</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterback R., Vuorinen T., Linna M., Susi P., Hyypiä T., Waris M. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg. Infect. Dis. 2009;15:1485–1488. doi: 10.3201/eid1509.090438.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1509.090438</ArticleId><ArticleId IdType="pmc">PMC2819858</ArticleId><ArticleId IdType="pubmed">19788821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Ding J., Cao J., Huang Q., Hong C., Yang B. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: Outbreaks of coxsackieviruses A10. J. Med. Virol. 2015;87:954–960. doi: 10.1002/jmv.24151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2010;14:e1076–e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann. Acad. Med. Singap. 2009;38:106–112. doi: 10.47102/annals-acadmedsg.V38N2p106.</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/annals-acadmedsg.V38N2p106</ArticleId><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Chieochansin T., Linsuwanon P., Korkong S., Thongkomplew S., Vichaiwattana P., Theamboonlers A., Poovorawan Y. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg. Infect. Dis. 2013;19:641–643. doi: 10.3201/eid1904.121666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., Wu C.L., Huang J.L., Fung C.P., Hsieh S.M., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE. 2013;8:e79783. doi: 10.1371/journal.pone.0079783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Mo Z., Liang Z., Zhang Y., Li R., Ong K.C., Wong K.T., Yang E., Che Y., Wang J., et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med. 2015;13:226. doi: 10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Cheng T., Zhu F., Li J., Wang Y., Li Y., Gao F., Yang L., Yao X., Shao J., et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE. 2013;8:e79599. doi: 10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Chen Z., Zheng K., Li X., Kong J., Duan X., Xiao X., Guo B., Luan R., Long L. Epidemiology of Hand, Foot, and Mouth Disease Before and After the Introduction of Enterovirus 71 Vaccines in Chengdu, China, 2009–2018. Pediatr. Infect. Dis. J. 2020;39:969–978. doi: 10.1097/inf.0000000000002745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/inf.0000000000002745</ArticleId><ArticleId IdType="pubmed">32433221</ArticleId></ArticleIdList></Reference><Reference><Citation>Anh N.T., Nhu L.N.T., Van H.M.T., Hong N.T.T., Thanh T.T., Hang V.T.T., Ny N.T.H., Nguyet L.A., Phuong T.T.L., Nhan L.N.T., et al. Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam. Emerg. Infect. Dis. 2018;24:654–662. doi: 10.3201/eid2404.171298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2404.171298</ArticleId><ArticleId IdType="pmc">PMC5875260</ArticleId><ArticleId IdType="pubmed">29553326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Yang H., Wang C., Yao X.J., Zhang H.L., Zhang R.L., He Y.Q. Genomic characteristics of coxsackievirus A8 strains associated with hand, foot, and mouth disease and herpangina. Arch. Virol. 2016;161:213–217. doi: 10.1007/s00705-015-2646-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-015-2646-1</ArticleId><ArticleId IdType="pubmed">26483280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., Liang Z. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum. Vaccines Immunother. 2014;10:360–367. doi: 10.4161/hv.27087.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.X., Song Y.F., Wang L., Zhang X.F., Hu Y.S., Hu Y.M., Xia J.L., Li J., Zhu F.C. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev. Vaccines. 2016;15:129–137. doi: 10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Laa Poh C. Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development. Virology. 2017;506:121–129. doi: 10.1016/j.virol.2017.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2017.03.017</ArticleId><ArticleId IdType="pubmed">28384566</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards K.M. Maternal antibodies and infant immune responses to vaccines. Vaccine. 2015;33:6469–6472. doi: 10.1016/j.vaccine.2015.07.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.07.085</ArticleId><ArticleId IdType="pubmed">26256526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson L.A. Session 1: Feeding and infant development breast-feeding and immune function. Proc. Nutr. Soc. 2007;66:384–396. doi: 10.1017/s0029665107005654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0029665107005654</ArticleId><ArticleId IdType="pubmed">17637091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakalidis V.S., Perrella S.L., Prosser S.A., Geddes D.T. Breastfeeding in a COVID-19 world. Curr. Opin. Clin. Nutr. Metab. Care. 2022;25:188–194. doi: 10.1097/mco.0000000000000821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mco.0000000000000821</ArticleId><ArticleId IdType="pubmed">35142722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Zhou C., Gao F., Zhu Q., Jiang Y., Ma X., Hu Y., Shi L., Wang X., Zhang C., et al. Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): Immunogenicity, efficacy and toxicology. Vaccine. 2021;39:4296–4305. doi: 10.1016/j.vaccine.2021.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.06.031</ArticleId><ArticleId IdType="pubmed">34167837</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chang J., Liu X., Yang J., Guo H., Wei W., Zhang W., Yu X.F. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J. Gen. Virol. 2014;95:1083–1093. doi: 10.1099/vir.0.063560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.063560-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Smith M., Carlyle S., Konopka-Anstadt J.L., Burns C.C., Konz J., Andino R., Macadam A. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 2023;619:135–142. doi: 10.1038/s41586-023-06212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="pubmed">37316671</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva D., Halken S., Singh C., Muraro A., Angier E., Arasi S., Arshad H., Beyer K., Boyle R., du Toit G., et al. Preventing food allergy in infancy and childhood: Systematic review of randomised controlled trials. Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol. 2020;31:813–826. doi: 10.1111/pai.13273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13273</ArticleId><ArticleId IdType="pubmed">32396244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedner S.G., Asarnoj A., Thulin H., Westman M., Konradsen J.R., Nilsson C. Food allergy and hypersensitivity reactions in children and adults—A review. J. Intern. Med. 2022;291:283–302. doi: 10.1111/joim.13422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13422</ArticleId><ArticleId IdType="pubmed">34875122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>